DOCSLIB.ORG

BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available BMJ Open: first published as 10.1136/bmjopen-2017-019819 on 21 January 2018. Downloaded from BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. Whe a atile is pulished e post the pee eiees’ oets ad the authos’ esposes online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay- per-view fees (http://bmjopen.bmj.com). If you hae ay uestios o BMJ Ope’s ope pee eie poess please eail [email protected] http://bmjopen.bmj.com/ on September 30, 2021 by guest. Protected copyright. BMJ Open: first published as 10.1136/bmjopen-2017-019819 on 21 January 2018. Downloaded from BMJ Open Comparative efficacy and acceptability of interventions for major depression in older persons: protocol for Bayesian network meta-analysis ForJournal: peerBMJ Open review only Manuscript ID bmjopen-2017-019819 Article Type: rotocol Date Submitted by the Author: 27-Sep-2017 Complete List of Authors: Liew, Tau Ming* Institute of Mental Health, Department of ,eriatric sychiatry <b. rimary Subject Mental health Heading-/b. Secondary Subject Heading: ,eriatric medicine major depression, older person, efficacy, acceptability, networ1 meta- 0eywords: analysis http://bmjopen.bmj.com/ on September 30, 2021 by guest. Protected copyright. For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml BMJ Open: first published as 10.1136/bmjopen-2017-019819 on 21 January 2018. Downloaded from Page 1 of 21 BMJ Open 1 2 3 Comparative efficacy and acceptability of interventions for major depression in older 4 5 persons: protocol for Bayesian network meta-analysis 6 7 8 9 Tau Ming Liew1, 2 10 11 1Department of Geriatric Psychiatry, Institute of Mental Health, Singapore 12 13 2 14 Saw Swee Hoc School of Public Health, National University of Singapore, Singapore 15 16 For peer review only 17 18 19 20 Correspondence to 21 22 Tau Ming Liew% 23 24 tau_ming_liew'imh.com.sg 25 26 27 Department of Geriatric Psychiatry, Institute of Mental Health, 28 29 10 Buang o View, Singapore ,3.707. 30 31 http://bmjopen.bmj.com/ 32 33 Keywords: ma1or depression% older person% efficacy% acceptability% networ meta3analysis 34 35 36 37 Number of words (Abstract): 287 38 39 on September 30, 2021 by guest. Protected copyright. 40 Number of words (main te t): 2,00. 41 42 Number of references: 25 43 44 Number of tables or figures: 1 45 46 47 48 49 50 51 52 53 54 55 56 57 58 1 59 60 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml BMJ Open: first published as 10.1136/bmjopen-2017-019819 on 21 January 2018. Downloaded from BMJ Open Page 2 of 21 1 2 3 ABSTRACT 4 5 6 7 Introduction: Ma1or depression is a leading cause of disability, and has been associated with 8 9 adverse effects in older persons. 6hile many pharmacological and non3pharmacological 10 11 interventions have been shown to be effective to address ma1or depression in older persons, 12 13 14 there has not been a meta3analysis that consolidates all the available interventions and 15 16 compare the relativeFor benefits peer of these reviewavailable interventions. only In this study, we aim to 17 18 conduct a systematic review and networ meta3analysis to compare the efficacy and 19 20 acceptability of all the nown pharmacological and non3pharmacological interventions for 21 22 ma1or depression in older persons. 23 24 Methods and analysis: 6e will search PubMed, Embase, PsycIN8O, CINAHL, 6eb of 25 26 27 Science, Scopus, Cochrane Central Register of Controlled Trials and references of other 28 29 review articles for articles related to the eywords of ”randomized trial?, ”major depression? 30 31 and ”older persons?. Two reviewers will independently select the eligible articles. 8or each http://bmjopen.bmj.com/ 32 33 included article, the two reviewers will independently extract the data and assess the ris of 34 35 bias using the Cochrane ris of bias tool. Bayesian networ meta3analyses will be conducted 36 37 to pool the efficacy Abased on standardized mean difference of depression score) and all3 38 39 on September 30, 2021 by guest. Protected copyright. 40 cause attrition across all the included studies. The ran ing probabilities for all interventions 41 42 will be estimated and the hierarchy of each interventions will be summarized as surface under 43 44 the cumulative ran ing curve ASUCRA). Meta3regression and sub3group analyses will also 45 46 be performed to evaluate the effect of study3level covariates. The Cuality of the evidence will 47 48 be assessed using the Grading of Recommendations Assessment, Development and 49 50 Evaluation AGRADE) approach. 51 52 53 Ethics and dissemination: The results will be disseminated through conference 54 55 presentations and peer3reviewed publications. They will provide the consolidated evidence to 56 57 58 2 59 60 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml BMJ Open: first published as 10.1136/bmjopen-2017-019819 on 21 January 2018. Downloaded from Page 3 of 21 BMJ Open 1 2 3 inform clinicians on the best choice of intervention to address major depression in older 4 5 persons. 6 7 Trial registration number: International Prospective Register for Systematic Reviews 8 9 APROSPERO) temporary registration number 7,7,5 Asubmitted on 30th August 2017). 10 11 12 13 14 15 16 For peer review only 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 http://bmjopen.bmj.com/ 32 33 34 35 36 37 38 39 on September 30, 2021 by guest. Protected copyright. 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 3 59 60 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml BMJ Open: first published as 10.1136/bmjopen-2017-019819 on 21 January 2018. Downloaded from BMJ Open Page 4 of 21 1 2 3 STRENGTHS AND ,IMITATIONS O. THIS ST/D0 4 5 6 7 • This systematic review and meta3analysis will provide a comprehensive summary on the 8 9 efficacy and acceptability of all available interventions for ma1or depression in older 10 11 12 persons. 13 14 • The results will provide the highest level of evidence to inform clinicians on the best 15 16 choice of treatment,For peerfrom among review the many available only pharmacological and non3 17 18 pharmacological interventions. 19 20 • This protocol has been developed in accordance with the Preferred Reporting Items for 21 22 23 Systematic Review and Meta3analysis Protocols APRISMA3P) statement and has been 24 25 submitted for registration with PROSPERO. 26 27 • The overall Cuality of evidence will be assessed using the Grading of Recommendations 28 29 Assessment, Development and Evaluation AGRADE) approach. 30 http://bmjopen.bmj.com/ 31 • This systematic review will be limited to studies in English language. 32 33 34 35 36 37 38 39 on September 30, 2021 by guest. Protected copyright. 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 4 59 60 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml BMJ Open: first published as 10.1136/bmjopen-2017-019819 on 21 January 2018. Downloaded from Page 5 of 21 BMJ Open 1 2 3 INTROD/CTION 4 5 6 7 8 Rationale 9 10 11 12 13 Ma1or depression has been identified by the 6orld Health Organization as one of the leading 14 15 cause of disability globally.1 2 In older persons, its prevalence rates rise with the increase in 16 For peer review only 17 medical comorbidities,3 with reported rates of up to ,D in community3dwelling older 18 19 persons,33, , to 10D in primary care3 5 and as high as 37D after critical care hospitalizations.3 20 21 7 Ma1or depression has a significant impact on the older populations and has been lin ed to 22 23 0 8 . 0 10 24 higher ris of suicide, myocardial infarction, stro e, all3cause mortality and increasing 25 0 26 health services utilization. 27 28 29 30 A wide range of interventions have been available to treat ma1or depression in older persons. 31 http://bmjopen.bmj.com/ 32 These include pharmacological and non3pharmacological interventions such as 33 34 antidepressants,11 antipsychotics,12 cognitive behavioural therapy,13 problem solving 35 36 10 1, 15 37 therapy, family interventions and physical exercise. Some of these interventions also 38 11 39 have had recent meta3analyses confirming their efficacy when compared to control groups. on September 30, 2021 by guest. Protected copyright. 40 13 10 15 41 However, none of the meta3analyses had provided comparisons among all the 42 43 pharmacological and non3pharmacological interventions to demonstrate the relative benefits 44 45 of each intervention. It is un nown whether all the interventions have comparable efficacy 46 47 and are eCually suitable for older persons with ma1or depression. 48 49 50 51 52 Objectives 53 54 55 56 57 58 5 59 60 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml BMJ Open: first published as 10.1136/bmjopen-2017-019819 on 21 January 2018.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0065218A1 Migeon Et Al
    US 2005.0065218A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0065218A1 Migeon et al. (43) Pub. Date: Mar. 24, 2005 (54) UTILIZATION OF ALVERINE, ALONE OR IN (30) Foreign Application Priority Data COMBINATION WITH TRICYCLC ANTDEPRESSANT OR A SPECIFIC Jun. 13, 2003 (FR).............................................. O307176 SEROTONIN REUPTAKE INHIBITOR FOR Apr. 30, 2004 (FR).............................................. O404639 THE TREATMENT OF DEPRESSION Publication Classification (76) Inventors: Jacques Migeon, Seattle, WA (US); Frederic Revah, Paris (FR) (51) Int. C.7 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - A61K 31/137 (52) U.S. Cl. .............................................................. 514/649 Correspondence Address: SESD LARDNER (57) ABSTRACT 3000 KSTREET NW WASHINGTON, DC 20007 (US) The present invention relates to the utilization of Alverine or its metabolites, alone or in combination with a tricyclic (21) Appl. No.: 10/866,079 antidepressant or a Specific Serotonin reuptake inhibitor, for the preparation of pharmaceutical compositions for the (22) Filed: Jun. 14, 2004 treatment of depression. 80 120 OO 8 O 6 O 40 20 t Excipicnts Alverine Alverine Alverine Imiprannine (1% methylcellulose) Citate Citrate Citrate 10 mg/kg 3 mg/kg 10 mg/kg 30 mg/kg Patent Application Publication Mar. 24, 2005 Sheet 1 of 4 US 2005/0065218 A1 Excipients Alverine Alveline Alveline Inipramine (1% methylcellulose) Citrate Citrate Citrate 10 mg/kg 3 mg/kg 10 mg/kg 30 mg/kg Fi gure US 2005/0065218A1 Imipramine 30 mg/kg Figure 2 Patent Application Publication Mar. 24, 2005 Sheet 3 of 4 US 2005/0065218A1 20 Vehicle + Whicule -- Averine Alvérine Vehicule + Alverine Vehicule imipramine 3 ring/kg it 3 mg/kg t- Impramine 10 mg/kg + 3 mg/kg Wellicule imipramine 10 mg/kg Vehicule 3 mg/kg Figure 3 Patent Application Publication Mar.
    [Show full text]
  • Info on Skin Testing
    Information on Skin Testing *Please review 1 week prior to testing* Your Doctor has ordered an allergy test for you. Your appointment has been made for: ___________________________________ at _______________________AM/PM at our (date) (time) _ Foulkstone / Limestone / Glasgow _ office. Skin tests are a method of testing for allergic reactions to substances, or allergens, in the environment. Our practice utilizes a test that involves no needles! We use a prick method which involves a series of small plastic applicators that carry a specific antigen which is placed on your arms. The types of allergens we test for include weeds, trees, grasses, molds, animal dander, dust mites and some foods. The testing will take 45 minutes. Please remember to wear comfortable clothing with short sleeves. Reactions can consist of itchy eyes, nose or throat, nasal congestion, runny nose, tightness in the throat or chest, wheezing, lightheadedness, hives or anaphylactic shock. Although this is very rare, our staff is fully prepared with emergency equipment and a physician is always on site. To ensure accurate testing results, certain medicines should be stopped 5 days prior to testing, although you should not stop medicines without talking to your prescribing physician. Medications that interfere with testing include but are not limited to: Antihistamines are medicines used to treat allergies, nausea, and dizziness. Many are found in over the counter cold medicines. They include, but are not limited to: ALAVERT / CLARITIN (LORATIDINE) DRAMAMINE (DIMENHYDRINATE)
    [Show full text]
  • Cyclic Antidepressant Drugs SI Conversion: [AUQ: Dr
    834 II: THERAPEUTIC DRUGS 127. Spiker DG, Pugh DD. Combining tricyclic and monoamine oxidase inhibi- 145. Chambost M, Liron L, Peillon D, et al. [Serotonin syndrome during fluoxetine tor antidepressants. Arch Gen Psychiatry 1976;33(7):828–830. poisoning in a patient taking moclobemide.] Can J Anaesth 2000;47(3):246– 128. Peebles-Brown AE. Hyperpyrexia following psychotropic drug overdose. 250. Anaesthesia 1985;40(11):1097–1099. 146. Myrenfors PG, Eriksson T, Sandsted CS, et al. Moclobemide overdose. J 129. Tuck JR, Punell G. Uptake of (3H)5-hydroxytryptamine and (3H)noradrenaline Intern Med 1993;233(2):113–115. by slices of rat brain incubated in plasma from patients treated with chlorimi- 147. Pounder DJ, Jones GR. Post-mortem drug redistribution––a toxicological pramine, imipramine or amitriptyline. J Pharm Pharmacol 1973;25(7):573–574. nightmare. Forensic Sci Int 1990;45(3):253–263. 130. Gillman PK. Successful treatment of serotonin syndrome with chlorproma- 148. Lichtenwalner MR, Tully RG, Cohn RD, et al. Two fatalities involving zine. Med J Aust 1996;165(6):345–346. phenelzine. J Anal Toxicol 1995;19(4):265–266. 131. Graham PM. Successful treatment of the toxic serotonin syndrome with 149. Yonemitsu K, Pounder DJ. Postmortem changes in blood tranylcypromine chlorpromazine. Med J Aust 1997;166(3):166–167. concentration: competing redistribution and degradation effects. Forensic 132. Tackley RM, Tregaskis B. Fatal disseminated intravascular coagulation fol- Sci Int 1993;59(2):177–184. lowing a monoamine oxidase inhibitor/tricyclic interaction. Anaesthesia 150. Baselt RC, Shaskan E, Gross EM. Tranylcypromine concentrations and 1987;42(7):760–763.
    [Show full text]
  • Dawson, S., Maund, E., Stuart, B., Moore, M., Christopher, D
    Dawson, S. , Maund, E., Stuart, B., Moore, M., Christopher, D., Geraghty, A. WA., & Kendrick, T. (2019). Managing Antidepressant Discontinuation: A Systematic Review. Annals of Family Medicine, 17(1), 52-60. https://doi.org/10.1370/afm.2336 Peer reviewed version License (if available): Other Link to published version (if available): 10.1370/afm.2336 Link to publication record in Explore Bristol Research PDF-document This is the accepted author manuscript (AAM). The final published version (version of record) is available online via the Annals of Family Medicine at https://doi.org/10.1370/afm.2336 . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ Supplemental materials for: Maund E, Stuart B, Moore M, et al. Managing antidepressant discontinuation: a systematic review. Ann Fam Med. 2019;17(1):52-60. 1 Supplemental APPENDIX 1 - SEARCH STRATEGIES MEDLINE Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to 23 March 2017 Search Query Items ID# found 1 exp ANTIDEPRESSIVE AGENTS/ 133782 2 exp NEUROTRANSMITTER UPTAKE INHIBITORS/ 133192 3 (psychotropic* or antidepress* or anti depress* or ((serotonin or norepinephrine or 136112 noradrenaline or nor epinephrine or nor adrenaline or neurotransmitt* or dopamine*) and (uptake or reuptake or re-uptake)) or noradrenerg* or antiadrenergic or anti adrenergic or SSRI* or SNRI* or TCA* or tricyclic* or tetracyclic* or heterocyclic*).ti,kf,hw.
    [Show full text]
  • Tricyclic Antidepressants Versus
    Jørgensen et al. Syst Rev (2021) 10:227 https://doi.org/10.1186/s13643-021-01789-0 PROTOCOL Open Access Tricyclic antidepressants versus ‘active placebo’, placebo or no intervention for adults with major depressive disorder: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis Caroline Kamp Jørgensen1* , Sophie Juul1,2,3, Faiza Siddiqui1, Marija Barbateskovic1, Klaus Munkholm4, Michael Pascal Hengartner5, Irving Kirsch6, Christian Gluud1 and Janus Christian Jakobsen1,7 Abstract Background: Major depressive disorder is a common psychiatric disorder causing great burden on patients and societies. Tricyclic antidepressants are frequently used worldwide to treat patients with major depressive disorder. It has repeatedly been shown that tricyclic antidepressants reduce depressive symptoms with a statistically signifcant efect, but the efect is small and of questionable clinical importance. Moreover, the benefcial and harmful efects of all types of tricyclic antidepressants have not previously been systematically assessed. Therefore, we aim to investigate the benefcial and harmful efects of tricyclic antidepressants versus ‘active placebo’, placebo or no intervention for adults with major depressive disorder. Methods: This is a protocol for a systematic review with meta-analysis that will be reported as recommended by Pre- ferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols, bias will be assessed with the Cochrane Risk of Bias tool—version 2, our eight-step procedure will be used to assess if the thresholds for clinical signifcance are crossed, Trial Sequential Analysis will be conducted to control random errors and the certainty of the evidence will be assessed with the Grading of Recommendations Assessment, Development and Evaluation approach.
    [Show full text]
  • Screening of 300 Drugs in Blood Utilizing Second Generation
    Screening of 300 Drugs in Blood Utilizing Second Generation Exactive Plus High-Resolution, Accurate Mass Spectrometer and ExactFinder Software Kristine Van Natta, Marta Kozak, Xiang He Thermo Fisher Scientific, San Jose, CA FIGURE 2. Schematic diagram of the Exactive Plus high-resolution accurate FIGURE 5. ExactFinder processing method and database. FIGURE 7. LODs for around 490 compounds For targeted screening, ExactFinder uses parameters set in processing method to Overview mass benchtop mass spectrometer. identify and confirm the presence of compound based on database values. Figure 8 Purpose: Evaluate Thermo Scientific Exactive Plus high performance bench-top mass Compound LOD Compound LOD Compound LOD Compound LOD shows data review results for one donor sample. In this method, compounds were 1‐(3‐Chlorophenyl)piperazine 5 Deacetyl Diltiazem 5 Lormetazepam 5 Perimetazine 5 identified by accurate mass within 5 ppm and retention time. Identity was further spectrometer for drug screening of whole blood for forensic toxicology purposes. 10‐hydroxycarbazepine 5 Demexiptiline 5 Loxapine 5 Phenacetin 5 5‐(p‐Methylphenyl)‐5‐phenylhydantoin 10 Des(2‐hydroxyethyl)opipramol 5 LSD 5 Phenazone 5 confirmed by isotopic pattern and presence of known fragments. Methods: Whole blood samples were processed by precipitation with ZnSO / 6‐Acetylcodeine 100 Desalkylflurazepam 5 Maprotiline 5 Pheniramine 5 4 6‐Methylthiopurine 5 Desipramine 5 Maraviroc 5 Phenobarbital 5 Matrix effects were observed to be compound dependent and were generally within methanol. Samples were injected onto an HPLC under gradient conditions and 6‐Monoacetylmorphine 5 Desmethylcitalopram 5 MBDB 5 Phenylbutazone 5 7(2,3dihydroxypropyl)Theophylline 5 Desmethylclozapine 50 MDEA 5 Phenytoin 10 ±50%.
    [Show full text]
  • Antidepressant Treatment for Postnatal Depression
    This is a repository copy of Antidepressant treatment for postnatal depression. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/163986/ Version: Published Version Article: Brown, Jennifer Valeska Elli orcid.org/0000-0003-0943-5177, Wilson, Claire A., Ayre, Karyn et al. (5 more authors) (2020) Antidepressant treatment for postnatal depression. Cochrane Database of Systematic Reviews. CD013560. ISSN 1469-493X https://doi.org/10.1002/14651858.CD013560 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Cochrane Library Cochrane Database of Systematic Reviews Antidepressant treatment for postnatal depression (Protocol) Brown JVE, Wilson CA, Ayre K, South E, Molyneaux E, Trevillion K, Howard LM, Khalifeh H Brown JVE, Wilson CA, Ayre K, South E, Molyneaux E, Trevillion K, Howard LM, Khalifeh H. Antidepressant treatment for postnatal depression. Cochrane Database of Systematic Reviews 2020, Issue 3. Art. No.: CD013560. DOI: 10.1002/14651858.CD013560. www.cochranelibrary.com Antidepressant treatment for postnatal depression (Protocol) Copyright © 2020 The Cochrane Collaboration.
    [Show full text]
  • Beta Blockers Herbs
    Accredited Asthma, Allergy, & Food Intolerance Center • 1009B Dupont Square North • Louisville, KY • 40207 • Phone (502)895 -3330 • Fax (502)895-3356 IMPORTANT LIST OF MEDICATIONS TO AVOID - REVIEW IMMEDIATELY ANTIHISTAMINES ANTIHISTAMINES (CONT.) TRICYCLIC ANTIDEPRESSANTS **STOP 10 days PRIOR TO TESTING** **STOP 2 DAYS or 48 Hours PRIOR TO TESTING** **STOP 10 days PRIOR TO TESTING** GENERIC NAME BRAND NAME GENERIC NAME BRAND NAME **Please contact the ordering physician Azelastine Astelin Acrivastine Semprex-D before stopping these medications.** Azelastine Optivar Olopatadine Pataday Cetirizine Zyrtec GENERIC NAME BRAND NAME Chlorcyclizine HCl Ahist Amitriptyline Elavil Chlorcyclizine HCl Stahist Medications for Dizziness/Motion Amitriptyline Endep Chlorpheniramine Aller-Chlor Sickness Amitriptyline Etrafon Chlorpheniramine Chlo-Amine **STOP 10 DAYS PRIOR TO TESTING** Amitriptyline Laroxyl Chlorpheniramine Chlorphen GENERIC NAME BRAND NAME Amitriptyline Limbitrol Chlorpheniramine Chlor-Trimeton Meclizine Hydrochloride Antivert Amitriptyline Tryptizol Chlorpheniramine C.P.M. Meclizine Dramamine Amitriptyline Vanatrip Chlorpheniramine Effidac-24 Amitriptylinoxide Ambivalon Chlorpheniramine Ridraman Amitriptylinoxide Amioxid Cimetidine Tagamet Amitriptylinoxide Equilibrin Clemastine Allerhist-1 BETA BLOCKERS Amoxampine Asendin Clemastine Contac 12 Hour Allergy **DO NOT TAKE these medications the MORNING Butriptyline Evadyne Clemastine Tavist-1 OF your appointment** Clomipramine Anafranil Cyproheptadine Periactin GENERIC NAME BRAND NAME
    [Show full text]
  • (73) Assignee: Epicept Corporation, Englewood E. E. E. N. "...O's E Cliffs, NJ (US) 6,245,781 B1 6/2001 Upadhyay Et Al
    USOO6638981B2 (12) UnitedO States Patent (10) Patent No.: US 6,638,981 B2 Williams et al. (45) Date of Patent: Oct. 28, 2003 (54) TOPICAL COMPOSITIONS AND METHODS 6,191,131 B1 2/2001. He et al. .................... 514/246 FOR TREATING PAIN 6,191,165 B1 2/2001 Ognyanov et al. .......... 514/523 6,197.830 B1 3/2001 Frome ........................ 514/654 (75) Inventors: Robert O. Williams, Austin, TX (US); 3.24-Y-2 R : E.aS C al.al ...........- - - - - - sy: Feng Zhang, Austin, TX (US) 6,225,324 B1 5/2001 Poss et al. .................. 514/316 (73) Assignee: Epicept Corporation, Englewood E. E. E. N. "...O's E Cliffs, NJ (US) 6,245,781 B1 6/2001 Upadhyay et al. .......... 514/321 - 6,251,903 B1 6/2001 Cai et al. .................... 514/249 (*) Notice: Subject to any disclaimer, the term of this 6.251948 B1 6/2001 Weber et al. ............... 514/634 patent is extended or adjusted under 35 6.255,302 B1 7/2001 Kelly et al. ............ 514/217.05 U.S.C. 154(b) by 0 days. 6,387,957 B1 5/2002 Frome ........................ 514/647 6,461,600 B1 10/2002 Ford ....................... 424/78.02 (21) Appl. No.: 09/931,293 FOREIGN PATENT DOCUMENTS (22) Filed: Aug. 17, 2001 EP O 107 376 A1 5/1984 (65) Prior Publication Data EP O 577 394 A1 1/1994 WO WO 93/10163 5/1993 US 2003/0082214 A1 May 1, 2003 WO WO 94/13643 6/1994 (51) Int. Cl. .............................................. A61K31/135 W. WO 94/13644 6/1994 WO WO 94/13661 6/1994 (52) U.S.
    [Show full text]
  • Supplemental Digital Content 1 Search Strategy (First Conducted on January 17, 2014; Second Retrieval on November 5, 2014)
    Supplemental Digital Content 1 Search strategy (first conducted on January 17, 2014; second retrieval on November 5, 2014) Cochrane Central Register of Controlled Trials and MEDLINE via OVID 1. exp chronic pain/ 2. Pain Management/ 3. Pain Measurement/ 4. pain*.mp. 5. 1 or 2 or 3 or 4 11. exp neoplasms/ 12. (neoplas* or cancer* or tumor* or tumour* or carcinoma* or malignan* or oncolog* or metasta* or sarcoma* or adenocarcinoma* or choriocarcinoma* or leukemia* or leukaemia*).mp. 13. 11 or 12 14. exp Anticonvulsants/ or exp Antidepressive Agents/ 15. (anticonvulsant* or antiepilept* or antidepressant* or anti-convulsant* or anti-epilept* or anti-depressant*).mp. 16. (acetazolamide or carbamazepine or clonazepam or divalproex or ethosuximide or ethotoin or felbamate or fosphenytoin or gabapentin or lacosamide or lamotrigine or levetiracetam or methsuximide or oxcarbazepine or phenobarbital or phenobarbitone or phenytoin or pregabalin or primidone or tiagabine or topiramate or trimethadione or valproate or valproic or vigabatrin or zonisamide).mp. 17. (agomelatine or amesergide or amineptine or amitriptyline or amoxapine or aripiprazole or benactyzine or brofaromine or bupropion or butriptyline or chlorimipramine or cianopramine or citalopram or clomipramine or clorgyline or clovoxamine or demexiptiline or desipramine or desvenlafaxine or dibenzepin or dimetacrine tartrate or dosulepin or dothiepin or doxepin or duloxetine or escitalopram or etoperidone or femoxetine or fezolamine fumarate or fluoxetine or fluvoxamine or ifoxetine or imipramine
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Comparative Efficacy and Tolerability of First-Generation and Newer
    Open Access Protocol BMJ Open: first published as 10.1136/bmjopen-2015-007768 on 9 September 2015. Downloaded from Comparative efficacy and tolerability of first-generation and newer-generation antidepressant medications for depressive disorders in children and adolescents: study protocol for a systematic review and network meta-analysis Xinyu Zhou,1 Bin Qin,1 Craig Whittington,2 David Cohen,3 Yiyun Liu,1 Cinzia Del Giovane,4 Kurt D Michael,5 Yuqing Zhang,1 Peng Xie1 To cite: Zhou X, Qin B, ABSTRACT et al Strengths and limitations of this study Whittington C, . Introduction: Depressive disorders are among the Comparative efficacy and most common psychiatric disorders in children and ▪ tolerability of first-generation This Bayesian network meta-analysis can inte- adolescents, and have adverse effects on their and newer-generation grate direct evidence with indirect evidence from antidepressant medications psychosocial functioning. Questions concerning the multiple treatment comparisons to estimate the for depressive disorders in efficacy and safety of antidepressant medications in the interrelations across all treatments. children and adolescents: treatment of depression in children and adolescents, ▪ We will comprehensively assess the efficacy, study protocol for led us to integrate the direct and indirect evidence tolerability, acceptability and suicide-related out- a systematic review and using network meta-analysis to create hierarchies of comes of first-generation and newer-generation BMJ network meta-analysis. these drugs. antidepressant medications for depression in Open 2015;5:e007768. Methods and analysis: Seven databases with children and adolescents. doi:10.1136/bmjopen-2015- PubMed, EMBASE, the Cochrane Library, Web of ▪ http://bmjopen.bmj.com/ 007768 Several subgroup and sensitivity analyses will Science, CINAHL, LiLACS and PsycINFO will be address some clinically relevant questions.
    [Show full text]